CLINICAL_TRIALS
trial_result
· 2022-06-14
Clinical Trial Update: Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma [Phase 2]
Summary
Phase 2 trial evaluating temozolomide with sorafenib in metastatic or unresectable melanoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED | Results posted: 2022-06-14